Dear,

Konsensus and X-STRA invite you on Wednesday 19 October at 8.00 am to share views on strategy, vision, innovation and leadership with Chris Buyse, CFO of ThromboGenics.

ThromboGenics is one of Europe’s most successful biotechnology companies. In recent years the company has made significant progress towards the goal of becoming a transforming force in ophthalmic medicine and innovative biopharmaceuticals. This success, combined with the potential of its lead product, ocriplasmin, has enabled the company to deliver significant returns to shareholders since its IPO in mid-2006.

Mr Chris Buyse has more than 20 years of experience in Finance and was previously  CFO of the Belgian biotechnology company CropDesign, acquired by BASF in the early 2007. 

Programme:

8h – 8h30       Registration + Breakfast

8h30 – 9h30   Presentation by Chris Buyse: “From idea to commercialisation through an IPO”

9h30-10h       Questions

10h – 11h       Networking opportunity

 Working language: 3-lingual - English, Dutch and French

Venue:

Provinciehuis Leuven – Provincieplein 1 – 3010 Leuven

Parking available in the building and on a walking distance from the train and bus station of Leuven

This event will give you an excellent opportunity to meet and brainstorm with other CxO’s.

If you wish to attend this conference and drink, please register before 13 October 2011.

Participation fee 45€ (Benefiting VZW Dennenhof)

YOUR SEAT IS RESERVED!

REGISTER NOW

We are looking forward to seeing you there.

Luc De Muynck

Managing Partner X-STRA

Helena Demuynck

Partner Konsensus

Nathalie Laroye

Partner Konsensus Interim Management

Luc Verhulst

Managing Partner X-STRA

More information on

www.Challenge-us.org

Partner: